Palemo Holdings
2778
Spancrete
5277
Renascience
4889
Oncolys BioPharma
4588
Kitagawa Seiki
6327
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 0.00%37.22B | 9.11%159.02B | -10.35%38.65B | 8.28%42.9B | 22.21%40.25B | 23.75%37.22B | 24.92%145.74B | 34.16%43.11B | 32.55%39.62B | 33.06%32.94B |
Cost of revenue | 0.00%33.05B | 5.00%138.55B | -6.52%33.91B | 2.69%37.16B | 12.47%34.44B | 14.43%33.05B | 21.13%131.96B | 20.18%36.28B | 29.25%36.18B | 27.80%30.62B |
Gross profit | 0.00%4.17B | 48.44%20.47B | -30.66%4.74B | 67.05%5.74B | 150.84%5.82B | 248.95%4.17B | 78.27%13.79B | 250.54%6.84B | 81.22%3.44B | 191.33%2.32B |
Operating expense | 0.00%2.83B | 13.99%11.78B | 16.93%3.23B | 9.11%2.85B | 13.66%2.87B | 16.22%2.83B | -0.31%10.33B | 23.02%2.76B | -6.38%2.61B | -12.48%2.53B |
Staff costs | ---- | 5.65%2.64B | ---- | ---- | ---- | ---- | -12.08%2.5B | ---- | ---- | ---- |
Selling and administrative expenses | ---- | 21.26%2.07B | ---- | ---- | ---- | ---- | -4.59%1.7B | ---- | ---- | ---- |
-General and administrative expense | ---- | 21.26%2.07B | ---- | ---- | ---- | ---- | -4.59%1.7B | ---- | ---- | ---- |
Research and development costs | ---- | 16.54%1.28B | ---- | ---- | ---- | ---- | -21.41%1.09B | ---- | ---- | ---- |
Other operating expenses | ---- | 15.11%5.8B | ---- | ---- | ---- | ---- | 15.90%5.04B | ---- | ---- | ---- |
Operating profit | 0.00%1.34B | 151.39%8.69B | -62.83%1.52B | 250.73%2.89B | 1,530.58%2.95B | 207.90%1.34B | 231.58%3.46B | 1,502.41%4.08B | 192.17%824M | 90.14%-206M |
Net non-operating interest income (expenses) | 0.00%-296M | -17.07%-1.2B | 0.00%-280M | -4.30%-291M | -34.82%-333M | -35.16%-296M | -169.03%-1.03B | -120.47%-280M | -121.43%-279M | -201.22%-247M |
Non-operating interest income | 0.00%53M | 92.14%269M | 80.00%108M | 162.50%84M | -7.69%24M | 140.91%53M | 34.62%140M | 71.43%60M | 45.45%32M | 13.04%26M |
Non-operating interest expense | 0.00%349M | 26.09%1.47B | 14.12%388M | 20.58%375M | 30.77%357M | 44.81%349M | 140.21%1.17B | 109.88%340M | 110.14%311M | 160.00%273M |
Net investment income | 0.00%675M | 203.79%881M | 177.27%305M | 27.88%-313M | 18.89%214M | 55.53%675M | -3.33%290M | -45.81%110M | -1,650.00%-434M | 267.35%180M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | 0.00%-15M | 264.71%56M | 104.17%1M | 335.71%66M | -42.86%4M | -236.36%-15M | -127.20%-34M | -366.67%-24M | -380.00%-28M | -90.91%7M |
Special income (charges) | -22.22%-11M | -51.45%-521M | -307.43%-1.32B | 8,010.00%811M | 41.67%-7M | 52.63%-9M | -262.26%-344M | -247.31%-323M | -96.15%10M | 40.00%-12M |
Less:Other special charges | 22.22%11M | -2,877.42%-861M | -760.00%-66M | -8,010.00%-811M | -41.67%7M | -52.63%9M | 118.02%31M | 900.00%10M | 96.14%-10M | -42.86%12M |
Less:Write off | ---- | 341.53%1.38B | ---- | ---- | ---- | ---- | 882.50%313M | ---- | ---- | ---- |
Other non-operating income (expenses) | -2.22%44M | 100.00%348M | 153.66%104M | 387.88%161M | -59.57%38M | 650.00%45M | -88.12%174M | -96.80%41M | -52.86%33M | 56.67%94M |
Income before tax | 0.00%1.74B | 228.23%8.26B | -90.86%329M | 2,560.00%3.33B | 1,663.39%2.86B | 269.43%1.74B | 376.68%2.52B | 268.85%3.6B | 119.17%125M | 90.86%-183M |
Income tax | 0.00%650M | 45.42%2.87B | -88.01%139M | 132.17%1.07B | 284.47%1.02B | 606.52%650M | 55.02%1.98B | 50.91%1.16B | 158.43%460M | 185.16%264M |
Net income | 0.00%1.09B | 898.70%5.38B | -92.17%191M | 775.45%2.26B | 512.98%1.85B | 197.32%1.09B | 124.68%539M | 1,078.74%2.44B | 59.71%-334M | 73.61%-447M |
Net income continuous operations | 0.00%1.09B | 896.85%5.38B | -92.22%190M | 773.73%2.26B | 512.98%1.85B | 197.41%1.09B | 124.74%540M | 1,073.56%2.44B | 59.64%-335M | 73.60%-447M |
Noncontrolling interests | 0.00%-60M | -2,000.00%-399M | -6,240.00%-317M | -355.56%-69M | 771.43%47M | -1,100.00%-60M | 121.43%21M | -103.94%-5M | -10.00%27M | 83.72%-7M |
Net income attributable to the company | 0.00%1.15B | 1,016.22%5.78B | -79.23%508M | 740.22%2.32B | 510.96%1.8B | 202.04%1.15B | 124.84%518M | 2,919.75%2.45B | 57.74%-363M | 73.47%-438M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 0.00%1.15B | 1,016.22%5.78B | -79.23%508M | 740.22%2.32B | 510.96%1.8B | 202.04%1.15B | 124.84%518M | 2,919.75%2.45B | 57.74%-363M | 73.47%-438M |
Gross dividend payment | ||||||||||
Basic earnings per share | 102.59%32.8 | 1,014.25%81.34 | -79.27%7.14 | 741.18%32.7 | 510.21%25.31 | 202.02%16.19 | 124.86%7.3 | 2,894.78%34.44 | 57.89%-5.1 | 73.47%-6.17 |
Diluted earnings per share | 102.59%32.8 | 1,014.25%81.34 | -79.25%7.14 | 739.73%32.6992 | 510.21%25.31 | 202.02%16.19 | 124.86%7.3 | 2,917.43%34.4158 | 57.79%-5.1114 | 73.47%-6.17 |
Dividend per share | 0 | 0.00%30 | 0.00%15 | 0 | 0.00%15 | 0 | 0.00%30 | 0.00%15 | 0 | 0.00%15 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |